Crossmark

ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

Crossref DOI link: https://doi.org/10.1016/j.patol.2019.11.002

Published Print: 2020-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Vicente-Baz, David

Paredes, Alfredo

Morán, Teresa

Massuti, Bartomeu

Reguart, Noemí

Álvarez, Rosa

Insa, Amelia

Juan-Vidal, Oscar

Artal, Ángel

Esteban, Emilio

García-Campelo, Rosario

Ortega-Granados, Ana L.

Diz, Pilar

González-Larriba, Jose L.

Terrasa, Josefa

de las Peñas, Ramón

Rodríguez-Abreu, Delvys

Callejo, Ángel

Márquez, Gloria

Provencio, Mariano
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2020-07-01
More Information

This article is maintained by: Elsevier

Article Title: ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

Journal Title: Revista Española de Patología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.patol.2019.11.002

Content Type: article

Copyright: © 2019 Sociedad Española de Anatomía Patológica. Published by Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below